Avior Wealth Management LLC Has $557,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Avior Wealth Management LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 4,227 shares of the company’s stock after selling 282 shares during the period. Avior Wealth Management LLC’s holdings in Neurocrine Biosciences were worth $557,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in Neurocrine Biosciences in the 1st quarter valued at approximately $27,000. Headinvest LLC acquired a new position in Neurocrine Biosciences in the third quarter valued at $28,000. KB Financial Partners LLC bought a new stake in Neurocrine Biosciences in the first quarter worth approximately $32,000. BluePath Capital Management LLC acquired a new stake in Neurocrine Biosciences in the third quarter worth $35,000. Finally, Covestor Ltd boosted its holdings in Neurocrine Biosciences by 431.0% in the first quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after acquiring an additional 306 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 0.5 %

Neurocrine Biosciences stock opened at $132.54 on Friday. The company has a market cap of $13.19 billion, a P/E ratio of 54.77 and a beta of 0.25. The business has a 50-day simple moving average of $136.16 and a two-hundred day simple moving average of $126.85. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. During the same period last year, the firm earned $0.88 EPS. Neurocrine Biosciences’s revenue for the quarter was up 25.0% compared to the same quarter last year. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the sale, the insider now owns 35,882 shares in the company, valued at $5,018,456.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the transaction, the insider now owns 35,882 shares in the company, valued at approximately $5,018,456.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,994 shares of company stock worth $27,205,009. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Citigroup reduced their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research note on Thursday, February 8th. Mizuho increased their price objective on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, February 8th. The Goldman Sachs Group increased their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Finally, StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $139.67.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.